{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:28:51Z","timestamp":1787020131506,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T00:00:00Z","timestamp":1603152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Intramural","award":["JIP\/Res\/Intra-MSc\/02\/\/2015-16"],"award-info":[{"award-number":["JIP\/Res\/Intra-MSc\/02\/\/2015-16"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>An increased osteoprotegerin (OPG) level has been reported in both type-2 diabetes mellitus (T2DM) and cardiovascular diease (CVD) that are linked to sympathovagal imbalance (SVI). We explored the link of osteoprotegerin with cardiovagal modulation in T2DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We assessed fasting serum OPG, high-sensitive C-reactive protein (hsCRP), glucose, insulin and lipid profile in patients having T2DM receiving oral antidiabetic drugs (OAD) (n\u2009=\u200942) compared with age, gender and body composition-matched healthy participants without diabetes (n\u2009=\u200942). Rate pressure product (RPP), spectral indices of heart rate variability (HRV) and body composition were recorded in both the groups. Association of HOMA-IR and OPG with various parameters were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Osteoprotegerin, HOMA-IR, hsCRP, coronary lipid risk factor were significantly increased, markers of cardiovagal modulation (TP, SDNN, RMSSD) were considerably decreased, ratio of low-frequency to high-frequency (LH-HF ratio), the indicator of SVI, and RPP, the marker of myocardial work stress were significantly higher in patients with diabetes, suggesting an overall elevated CVD risks in them. HOMA-IR was correlated with RMSSD, lipid risk factors and OPG. Rise in OPG was correlated with decreased cardiovagal modulation in patients with diabetes. There was significant contribution of OPG in decreasing TP, suggesting impaired cardiovagal modulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>T2DM patients receiving OAD had higher cardiometabolic risks compared to age, gender and body composition-matched healthy individuals. Increased level of OPG is linked to decreased cardiovagal modulation in T2DM patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-020-01729-1","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T07:03:27Z","timestamp":1603177407000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Increased osteoprotegerin level is associated with impaired cardiovagal modulation in type-2 diabetic patients treated with oral antidiabetic drugs"],"prefix":"10.1186","volume":"20","author":[{"given":"M. R.","family":"Jasmine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8887-8357","authenticated-orcid":false,"given":"Nivedita","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayaprakash","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Velkumary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. K.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,20]]},"reference":[{"key":"1729_CR1","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S0140-6736(16)00618-8","volume":"387","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2016","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387:1513\u201330.","journal-title":"Lancet"},{"key":"1729_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4066\/AMJ.2014.1979","volume":"7","author":"SA Kaveeshwar","year":"2014","unstructured":"Kaveeshwar SA, Cornwall J. The current state of diabetes mellitus in India. Australas Med J. 2014;7:45\u20138.","journal-title":"Australas Med J"},{"issue":"suppl 2","key":"1729_CR3","doi-asserted-by":"publisher","first-page":"S314","DOI":"10.2337\/dc09-S330","volume":"32","author":"D Versari","year":"2009","unstructured":"Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care. 2009;32(suppl 2):S314\u201321.","journal-title":"Diabetes Care"},{"key":"1729_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/653789","volume":"2013","author":"ASM de Matheus","year":"2013","unstructured":"de Matheus ASM, Tannus LRM, Cobas RA, Palma CCS, Negrato CA, de Gomes MB. Impact of diabetes on cardiovascular disease: an update. Int J Hypertens. 2013;2013:1\u201315.","journal-title":"Int J Hypertens"},{"issue":"Suppl 1","key":"1729_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1055\/s-2005-861371","volume":"37","author":"LM Rasmussen","year":"2005","unstructured":"Rasmussen LM, Ledet T. Osteoprotegerin and diabetic macroangiopathy. Horm Metab Res. 2005;37(Suppl 1):90\u20134.","journal-title":"Horm Metab Res"},{"key":"1729_CR6","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1161\/01.CIR.0000127957.43874.BB","volume":"109","author":"S Kiechl","year":"2004","unstructured":"Kiechl S. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109:2175\u201380.","journal-title":"Circulation"},{"key":"1729_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1530\/eje.0.1490039","volume":"149","author":"ST Knudsen","year":"2003","unstructured":"Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol. 2003;149:39\u201342.","journal-title":"Eur J Endocrinol"},{"key":"1729_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1464-5491.2010.02940.x","volume":"27","author":"M Nybo","year":"2010","unstructured":"Nybo M, Poulsen MK, Grauslund J, Henriksen JE, Rasmussen LM. Plasma osteoprotegerin concentrations in peripheral sensory neuropathy in type 1 and type 2 diabetic patients. Diabet Med. 2010;27:289\u201394.","journal-title":"Diabet Med"},{"key":"1729_CR9","first-page":"1","volume":"2014","author":"S Tavintharan","year":"2014","unstructured":"Tavintharan S, Pek LT, Liu JJ, Ng XW, Yeoh LY, Lim SC, Sum CF. Osteoprotegerin is independently associated with metabolic syndrome and microvascular complications in type 2 diabetes mellitus. Diabetes Vasc Dis Res. 2014;2014:1\u20134.","journal-title":"Diabetes Vasc Dis Res"},{"key":"1729_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1055\/s-0028-1085425","volume":"117","author":"HM Terekeci","year":"2009","unstructured":"Terekeci HM, Senol MG, Top C, Sahan B, Celik S, Sayan O, et al. Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy. Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc. 2009;117:119\u201323.","journal-title":"Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc"},{"key":"1729_CR11","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jdiacomp.2015.12.012","volume":"30","author":"RE Maser","year":"2016","unstructured":"Maser RE, Lenhard MJ, Pohlig RT, Balagopal PB. Osteopontin and osteoprotegerin levels in type 2 diabetes and their association with cardiovascular autonomic function. J Diabetes Complicat. 2016;30:507\u201310.","journal-title":"J Diabetes Complicat"},{"key":"1729_CR12","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s13105-013-0261-8","volume":"69","author":"J Suliburska","year":"2013","unstructured":"Suliburska J, Bogdanski P, Gajewska E, Kalmus G, Sobieska M, Samborski W. The association of insulin resistance with serum osteoprotegerin in obese adolescents. J Physiol Biochem. 2013;69:847\u201353.","journal-title":"J Physiol Biochem"},{"key":"1729_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13098-015-0042-3","volume":"7","author":"CN Ayina Ayina","year":"2015","unstructured":"Ayina Ayina CN, Sobngwi E, Essouma M, Noubiap JJN, Boudou P, Etoundi Ngoa LS, et al. Osteoprotegerin in relation to insulin resistance and blood lipids in sub-Saharan African women with and without abdominal obesity. Diabetol Metab Syndr. 2015;7:47.","journal-title":"Diabetol Metab Syndr"},{"key":"1729_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2217\/fca.12.80","volume":"9","author":"GK Pal","year":"2013","unstructured":"Pal GK, Pal P, Nanda N, Amudharaj D, Adithan C. Cardiovascular dysfunctions and sympathovagal imbalance in hypertension and prehypertension: physiological perspectives. Future Cardiol. 2013;9:53\u201369.","journal-title":"Future Cardiol"},{"key":"1729_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4103\/2348-8093.137398","volume":"1","author":"J Indumathy","year":"2014","unstructured":"Indumathy J, Pal GK, Pal P. Sympathovagal imbalance in obesity: cardiovascular perspectives. Int J Clin Exp Physiol. 2014;1:93\u2013100.","journal-title":"Int J Clin Exp Physiol"},{"key":"1729_CR16","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/PSY.0000000000000290","volume":"78","author":"LR Wulsin","year":"2016","unstructured":"Wulsin LR, Horn PS, Perry JL, Massaro JM, D\u2019Agostino RB Sr. The contribution of autonomic imbalance to the development of metabolic syndrome. Psychosom Med. 2016;78:474\u201380.","journal-title":"Psychosom Med"},{"key":"1729_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3109\/07435800.2014.920350","volume":"40","author":"S Kuppusamy","year":"2015","unstructured":"Kuppusamy S, Pal GK, Habeebullah S, Ananthanarayanan PH, Pal P. Association of sympathovagal imbalance with cardiovascular risks in patients with polycystic ovary syndrome. Endocr Res. 2015;40:37\u201343.","journal-title":"Endocr Res"},{"key":"1729_CR18","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.amjcard.2013.07.040","volume":"112","author":"GK Pal","year":"2013","unstructured":"Pal GK, Adithan C, Ananthanarayanan PH, Pal P, Nanda N, Durgadevi T, Syamsunderkiran AN, Lalitha V, Dutta TK. Association of sympathovagal imbalance with cardiovascular risks in young prehypertensives. Am J Cardiol. 2013;112:1757\u201362.","journal-title":"Am J Cardiol"},{"issue":"11","key":"1729_CR19","doi-asserted-by":"publisher","first-page":"e78072","DOI":"10.1371\/journal.pone.0078072","volume":"8","author":"GK Pal","year":"2013","unstructured":"Pal GK, Adithan C, Ananthanarayanan PH, Pal P, Nanda N, Durgadevi T, et al. Sympathovagal imbalance contributes to prehypertension status and cardiovascular risks attributed by insulin resistance, inflammation, dyslipidemia and oxidative stress in first degree relatives of type 2 diabetics. PLoS ONE. 2013;8(11):e78072.","journal-title":"PLoS ONE"},{"key":"1729_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jdi.12042","volume":"4","author":"AI Vinik","year":"2013","unstructured":"Vinik AI, Erbas T, Casellini CM. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig. 2013;4:4\u201318.","journal-title":"J Diabetes Investig"},{"key":"1729_CR21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1542-474X.1996.tb00275.x","volume":"1","author":"M Malik","year":"1996","unstructured":"Malik M. Heart rate variability. Ann Noninvasive Electrocardiol. 1996;1:151\u201381.","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"1729_CR22","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1161\/01.CIR.94.11.2850","volume":"94","author":"H Tsuji","year":"1996","unstructured":"Tsuji H, Larson MG, Venditti FJ Jr, Manders ES, Evans JC, Feldman CL, et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation. 1996;94:2850\u20135.","journal-title":"Circulation"},{"key":"1729_CR23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1080\/10641960802621333","volume":"31","author":"GK Pal","year":"2009","unstructured":"Pal GK, Shyma P, Habeebullah S, Shyjus P, Pal P. Spectral analysis of heart rate variability for early prediction of pregnancy-induced hypertension. Clin Exp Hypertens. 2009;31:330\u201341.","journal-title":"Clin Exp Hypertens"},{"key":"1729_CR24","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1161\/01.CIR.93.5.1043","volume":"93","author":"Task Force Report","year":"1996","unstructured":"Task Force Report. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Circulation. 1996;93:1043\u201365.","journal-title":"Circulation"},{"key":"1729_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1471-2261-12-54","volume":"12","author":"GK Pal","year":"2012","unstructured":"Pal GK, Adithan C, Ananthanarayanan PH, Dutta TK, Pal P, Nanda N, et al. Body mass index contributes to sympathovagal imbalance in prehypertensives. BMC Cardiovasc Disord. 2012;12:54.","journal-title":"BMC Cardiovasc Disord"},{"key":"1729_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.orcp.2014.01.007","volume":"9","author":"J Indumathy","year":"2015","unstructured":"Indumathy J, Pal GK, Pal P, Ananthanarayanan PH, Parija SC, Balachander J, et al. Association of sympathovagal imbalance with obesity indices, and abnormal metabolic biomarkers and cardiovascular parameters. Obes Res Clin Pract. 2015;9:55\u201366.","journal-title":"Obes Res Clin Pract"},{"key":"1729_CR27","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.metabol.2007.05.015","volume":"56","author":"N Nanda","year":"2007","unstructured":"Nanda N, Bobby Z, Hamide A, Koner BC, Sridhar MG. Association between oxidative stress and coronary lipid risk factors in hypothyroid women is independent of body mass index. Metabolism. 2007;56:1350\u20135.","journal-title":"Metabolism"},{"key":"1729_CR28","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1055\/s-0034-1396864","volume":"123","author":"A Esteghamati","year":"2015","unstructured":"Esteghamati A, Azizi R, Ebadi M, Noshad S, Mousavizadeh M, Afarideh M, et al. The comparative effect of pioglitazone and metformin on serum osteoprotegerin, adiponectin and intercellular adhesion molecule concentrations in patients with newly diagnosed type 2 diabetes: a randomized clinical trial. Exp Clin Endocrinol Diabetes. 2015;123:289\u201395.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"1729_CR29","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1475-2840-10-67","volume":"10","author":"WJ Chen","year":"2011","unstructured":"Chen WJ, Rijzewijk LJ, van der Meer RW, Heymans MW, Duinkerken E, Lubberink M, et al. Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men. Cardiovasc Diabetol. 2011;10:67. https:\/\/doi.org\/10.1186\/1475-2840-10-67.","journal-title":"Cardiovasc Diabetol"},{"key":"1729_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9649-6","author":"E Sofer","year":"2015","unstructured":"Sofer E, Shargorodsky M. Effect of metformin treatment on circulating osteoprotegerin in patients with nonalcoholic fatty liver disease. Hepatol Int. 2015. https:\/\/doi.org\/10.1007\/s12072-015-9649-6.","journal-title":"Hepatol Int"},{"key":"1729_CR31","first-page":"18","volume":"20","author":"PP Dimitrow","year":"2011","unstructured":"Dimitrow PP, Jawie\u0144 M, Gackowski A. The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis. J Heart Valve Dis. 2011;20:18\u201322.","journal-title":"J Heart Valve Dis"},{"key":"1729_CR32","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3389\/fpubh.2017.00258","volume":"5","author":"F Schaffer","year":"2017","unstructured":"Schaffer F, Ginsberg JP. An overview of heart rate variability metrices and norms. Front Public Health. 2017;5:258. https:\/\/doi.org\/10.3389\/fpubh.2017.00258.","journal-title":"Front Public Health"},{"key":"1729_CR33","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","volume":"89","author":"WS Simonet","year":"1997","unstructured":"Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang M-S, L\u00fcthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309\u201319.","journal-title":"Cell"},{"key":"1729_CR34","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1159\/000257339","volume":"47","author":"R Candido","year":"2010","unstructured":"Candido R, Toffoli B, Corallini F, Bernardi S, Zella D, Voltan R, et al. Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo. J Vasc Res. 2010;47:252\u201361.","journal-title":"J Vasc Res"},{"key":"1729_CR35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.bbrc.2011.02.117","volume":"407","author":"M Schoppet","year":"2011","unstructured":"Schoppet M, Kavurma MM, Hofbauer LC, Shanahan CM. Crystallizing nanoparticles derived from vascular smooth muscle cells contain the calcification inhibitor osteoprotegerin. Biochem Biophys Res Commun. 2011;407:103\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"1729_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.mce.2014.06.004","volume":"394","author":"S Bernardi","year":"2014","unstructured":"Bernardi S, Fabris B, Thomas M, Toffoli B, Tikellis C, Candido R, et al. Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. Mol Cell Endocrinol. 2014;394:13\u201320.","journal-title":"Mol Cell Endocrinol"},{"key":"1729_CR37","first-page":"289","volume":"5","author":"CPC Villacampa","year":"2016","unstructured":"Villacampa CPC. Osteoprotegerin: a promising biomarker in the metabolic syndrome\u2014new perspectives. Biochem Anal Biochem. 2016;5:289.","journal-title":"Biochem Anal Biochem"},{"key":"1729_CR38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4172\/2153-0769.1000172","volume":"6","author":"AE Berezin","year":"2016","unstructured":"Berezin AE. Can osteoprotegerin be a target of therapy in type 2 diabetes mellitus? Metabolomics. 2016;6:2. https:\/\/doi.org\/10.4172\/2153-0769.1000172.","journal-title":"Metabolomics"},{"key":"1729_CR39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3109\/07435800.2015.1076454","volume":"41","author":"GS Keerthi","year":"2016","unstructured":"Keerthi GS, Pal P, Pal GK, Sahoo JP, Sridhar MG, Balachander J. Attenuated baroreflex sensitivity in normotensive prediabetes and diabetes in Indian adults. Endocr Res. 2016;41:89\u201397.","journal-title":"Endocr Res"},{"key":"1729_CR40","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jcjd.2017.01.008","volume":"42","author":"P Auroprajna","year":"2018","unstructured":"Auroprajna P, Naik BM, Sahoo JP, Keerthi GS, Pavanya M, Pal GK. Association of sympathovagal imbalance with cognitive impairment in type 2 diabetes in adults. Can J Diabetes. 2018;42:44\u201350.","journal-title":"Can J Diabetes"},{"key":"1729_CR41","doi-asserted-by":"publisher","first-page":"198","DOI":"10.4103\/2230-8210.83406","volume":"15","author":"S Sucharita","year":"2011","unstructured":"Sucharita S, Idiculla J, Vaz M, Bantwal G, Ayyar V. Autonomic nervous system function in type 2 diabetes using conventional clinical autonomic tests, heart rate and blood pressure variability measures. Indian J Endocrinol Metab. 2011;15:198.","journal-title":"Indian J Endocrinol Metab"},{"key":"1729_CR42","doi-asserted-by":"publisher","first-page":"243","DOI":"10.4103\/2348-8093.149747","volume":"1","author":"GK Pal","year":"2014","unstructured":"Pal GK. Resting heart rate is the index of cardiovascular health. Int J Clin Exp Physiol. 2014;1:243\u20134.","journal-title":"Int J Clin Exp Physiol"},{"key":"1729_CR43","unstructured":"Pal GK, Pal P, Nanda N. Regulation of blood pressure. In: Comprehensive textbook of medical physiology, 2nd edn. Jaypee Publishers, New Delhi. 2019: 445\u201363."},{"key":"1729_CR44","first-page":"50Se55S","volume":"12","author":"WB White","year":"1999","unstructured":"White WB. Heart rate and the rate-pressure product as determinants of cardiovascular risk in patients with hypertension. Am J Hypertens. 1999;12:50Se55S.","journal-title":"Am J Hypertens"},{"key":"1729_CR45","first-page":"97","volume":"29","author":"GK Pal","year":"2009","unstructured":"Pal GK. Importance of vagal tone in health promotion. Biomedicine. 2009;29:97\u20139.","journal-title":"Biomedicine"},{"issue":"3 Pt 2","key":"1729_CR46","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1161\/01.HYP.27.3.619","volume":"27","author":"JS Petersen","year":"1996","unstructured":"Petersen JS, DoBona GF. Acute sympathoinhibitory actions of metformin in spontaneously hypertensive rats. Hypertension. 1996;27(3 Pt 2):619\u201325.","journal-title":"Hypertension"},{"key":"1729_CR47","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.amjhyper.2003.11.006","volume":"17","author":"D Manzella","year":"2004","unstructured":"Manzella D, Grella R, Esposito K, Giugliano D, Barbagallo M, Paolisso G. Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration. Am J Hypertens. 2004;17:223\u20137.","journal-title":"Am J Hypertens"},{"key":"1729_CR48","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ijcard.2009.04.048","volume":"144","author":"CH Saely","year":"2010","unstructured":"Saely CH, Eber B, Pfeiffer KP, Drexel H, KIFE-IN-KIFE Study Group. Low serum LDL cholesterol in patients with type 2 diabetes: an analysis on two different populations. Int J Cardiol. 2010;144:394\u20138.","journal-title":"Int J Cardiol"},{"key":"1729_CR49","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3389\/fphys.2018.00424","volume":"9","author":"ME van den Berg","year":"2018","unstructured":"van den Berg ME, Rijnbeek PR, Niemeijer MN, Hofman A, van Herpen G, Bots ML, et al. Normal values of corrected heart-rate variability in 10-second electrocardiograms for all ages. Front Physiol. 2018;9:424.","journal-title":"Front Physiol"},{"key":"1729_CR50","doi-asserted-by":"publisher","first-page":"e13287","DOI":"10.1111\/psyp.13287","volume":"56","author":"EJC de Geus","year":"2019","unstructured":"de Geus EJC, Gianaros PJ, Brindle RC, Jennings JR, Berntson GG. Should heart rate variability be \u201ccorrected\u201d for heart rate? Biological, quantitative, and interpretive considerations. Psychophysiology. 2019;56:e13287.","journal-title":"Psychophysiology"},{"key":"1729_CR51","doi-asserted-by":"publisher","first-page":"23","DOI":"10.4278\/ajhp.130131-QUAN-52","volume":"29","author":"GK Pal","year":"2014","unstructured":"Pal GK, Ganesh V, Karthik S, Nanda N, Pal P. The effects of short-term relaxation therapy on indices of heart rate variability and blood pressure in young adults. Am J Health Promot. 2014;29:23\u20138.","journal-title":"Am J Health Promot"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01729-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-020-01729-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01729-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T20:12:58Z","timestamp":1634674378000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-020-01729-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,20]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1729"],"URL":"https:\/\/doi.org\/10.1186\/s12872-020-01729-1","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,20]]},"assertion":[{"value":"10 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the JIPMER Institute ethics committee [JIP\/IEC\/SC\/2015\/23\/842]. All data used in this study were anonymised and coded before its use. Written informed consent was obtained from each participant after explaining the purpose and procedure and their contribution in the study in their vernacular language.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"453"}}